论文部分内容阅读
Simvastatin(SIM)是一种强效HMG-C0A还原酶抑制剂,其在结构和药理特性方面与lovastatin非常接近,但作用较后者强,且每日1次给药即可。本文采用多中心随机双盲试验评价了SIM对高胆固醇(CH)血症的安全性和疗效,并与普罗布可(PRO)进行比较。方法 243例高CH血症病人,其中家族性高CH血症134例,非家族性高CH血症109例。所有病人在开始安慰剂治疗前停用一切降脂药至少4周。全部病人在4周安慰剂治疗后随机口服SIM20mg每日1次(82
Simvastatin (SIM) is a potent HMG-C0A reductase inhibitor that is very similar in structure and pharmacological properties to lovastatin but more potent than the latter and administered once daily. In this paper, we evaluated the safety and efficacy of SIM on hypercholesterolemia in a multicenter, randomized, double-blind trial compared with Pro (PRO). Methods 243 cases of hypercholesterolemia patients, including 134 cases of familial hypercholesterolemia, 109 cases of non-familial hypercholesterolemia. All patients discontinued all lipid-lowering drugs for at least 4 weeks before starting placebo treatment. All patients were randomized to oral SIM20mg orally once daily after 4 weeks of placebo treatment (82